5Kunstyr J, Lips M, Belohlavek J, et al. Sponta- neous delivery duringveno - venous extracor- poreal membrane oxygenation in swineinfluen- za - related acute respiratory failure [ J ]. Acta AnaesthesiolScand, 2010, 54 ( 9 ) : 1154 - 1155.
6Ribichini F, Tomai F, Reimers B, et al. Clini- cal outcome after endovascuIar, surgical or hy- brid revascularisation in patients with com- bined carotid and coronary artery disease:the Finalised Research In ENDovascular Strategies Study Group ( FRIENDS ) [ J ]. EuroInterven- tion,2010,6(3) :328 -335.
6Rosen DA, Morris JL, Rosen KR, et al. Nalmefene to prevent epidural narcotic side effects in pediatric patients: a pharmacokinetic and safety study [J]. Pharmacotherapy, 2000, 20 (7): 745-9.
7Li P, Chen X, Dai X, et al. Application of a sensitive liquid chromatographic/tandem mass spectrometric method to pharmacokinetic study of nalmefene in humans [ J ]. J Chromatogr B Analyt Technol Biomed Life Sci, 2007, 852(1-2): 479-84.
8Veng Pedersen P, Wilhelm JA, Zakszewski TB, et al. Duration of opioid antagonism by nalmefene and naloxone in the dog: an integrated pharmacokinetic/pharmaeodynamic comparison [ J ]. J Pharm Sci, 1995, 84(9): 1101-6.
9Frye RF, Matzke GR, Jallad NS, et al. The effect of age on the pharmacokineties of the opioid antagonist nalmefene [J ]. Br J Clin Pharmacol, 1996, 42(3): 301-6.
10Matzke GR, Frye RF, Alexander AC, et al. The effect of renal insufficiency and hemodialysis on the pharmacokinetics of nalmefene[J]. J Clin Pharmacol, 1996, 36(2): 144-51.
8Ingman K,Hagelberg N,Aalto S,et al.Prolonged central mu- opioid receptor occupancy after single and repeated nalmefene dosing[J].Neuropsgdo pharmacology,2005,30(12):2455-2253.
